卵巣がん治療薬の世界市場 - 2024年～2032年

卵巣がん治療薬の世界市場は、2023年に35億8,000万米ドルに達し、2032年には62億7,000万米ドルに達すると予測され、予測期間2024-2031年のCAGRは6.4％で成長します。

卵巣がんとは、女性の生殖器系の主要部分である卵巣、卵管、腹膜に異常ながん細胞が増殖することです。卵巣はさまざまな細胞からできており、細胞の種類によって卵巣がんは上皮性がん、胚細胞腫瘍、間質細胞腫瘍に分類されます。

卵巣がんは女性の間で死亡率の高いがんの一つです。世界保健機関（WHO）および国際がん研究機関の予測によると、2022年には20万7000人の女性が卵巣がんにより死亡し、2030年には死亡例が25万人に達すると予想されています。

卵巣がんの治療法には、主に手術、化学療法、標的薬による維持療法があります。治療の種類は卵巣がんのステージによって異なります。

市場力学：

促進要因と抑制要因

卵巣がんの罹患率と死亡率の上昇。

卵巣がんは、女性のがん関連死亡の主要原因のひとつです。このがんは侵攻性が強く、全患者の70％近くが初回治療後18ヵ月で再発を経験します。世界的に、卵巣がんは女性の健康上の大きな問題となっています。卵巣がん患者の生存率は低く、米国国立がん研究所のSurveillance, Epidemiology, and End Results（SEER）プログラムによれば、全5年生存率は50.8％です。

さらに、卵巣がんの罹患率は上昇の一途をたどっています。国際がん研究機関の統計によれば、新規症例数は2022年の324,600人から2030年には381,600人、2040年には447,500人になると予測されています。死亡率も同様に上昇しており、2022年の207,000人から2030年には250,100人、2040年には303,700人が死亡すると予測されています。

このような罹患率と死亡率の上昇が、予測期間における先進的治療薬の需要を促進すると予想されます。

先進治療薬の高額な治療費は治療率を妨げ、市場の成長を抑制する可能性があります。

いくつかの革新的な治療法が、化学療法とともに卵巣がんに使用されることが規制当局によって承認されました。これらの革新的療法には、モノクローナル抗体や酵素ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤などの標的療法が含まれます。これらの薬剤は卵巣がんの再発を抑え、進行を遅らせるために処方されます。しかし、これらの薬剤は高価であり、患者の経済的負担が大きいです。この高コストが、低・中所得層の患者集団における採用率の低下を招いている可能性があります。

例えば、2024年2月にPLoS ONE誌に掲載された研究では、マレーシアにおけるオラパリブによる卵巣がん患者の治療は高額であり、3万3,213米ドルの増分費用が反映される可能性があると述べられています。オラパリブ治療を受けた患者の平均余命は3.05年延びた。このことは、獲得生命年あたり1万895米ドルの増分費用効果比（ICER）を反映しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 卵巣がんの発生率と死亡率が上昇しています。
    • 製品開発活動の活発化
  • 抑制要因
    • 先進治療の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析

第6章 タイプ別

• 上皮性卵巣がん
• 胚細胞腫瘍
• 間質細胞腫瘍
• 境界悪性腫瘍

第7章 薬剤クラス別

• 化学療法
  • カルボプラチン
  • シスプラチン
  • パクリタキセル
  • ドセタキセル
  • その他
• 標的療法
  • モノクローナル抗体
  • PARP阻害剤
  • オラパリブ
  • ニラパリブ
  • ルカパリブ
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• AbbVie Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• AstraZeneca.
• Merck & Co., Inc.
• GSK plc.
• pharmaand GmbH.
• Pfizer Inc.
• Amneal Pharmaceuticals LLC.
• Amgen, Inc.
• Sanofi
• Teva Pharmaceuticals USA, Inc.

第11章 付録

The global ovarian cancer drugs market reached US$ 3.58 billion in 2023 and is expected to reach US$ 6.27 billion by 2032, growing at a CAGR of 6.4% during the forecast period 2024-2031.

Ovarian cancer is the growth of abnormal cancerous cells in the ovaries, fallopian tube, or peritoneum- the major parts of the woman's reproductive system. Ovaries are made up of different cells, and depending on the neoplasms in cell type, ovarian cancers are categorized into epithelial carcinomas, germ cell tumors, and stromal cell tumors.

Ovarian cancer is one of the highly mortal cancers among women. Globally, 207k women were mortalized due to ovarian cancer in 2022, and in 2030, the mortal cases are expected to reach 250k, as projected by the World Health Organization, and International Agency for Research on Cancer.

The treatment modalities for ovarian cancer primarily include surgery, chemotherapy, and maintenance therapy with targeted drugs. The type of treatment varies on the stages of ovarian cancer.

Market Dynamics: Drivers & Restraints

Rising incidence and mortality of ovarian cancer.

Ovarian cancer is one of the leading causes of oncology-related deaths among women. The cancer is aggressive and nearly 70% of all patients experience recurrence in 18 months after the initial treatment. Globally, ovarian cancer has become a major health concern among women population. The survival rate among patients with ovarian cancer is low, with an overall five-year survival rate of 50.8%, as stated by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program.

Moreover, the incidence rate of ovarian cancer is continuously rising. As per the International Agency for Research on Cancer statistics, new cases are projected to be 381,600 in 2030 and 447,500 in 2040, from 324,600 in 2022. The Mortality rate is similarly rising, with 250,100 deaths to occur in 2030, and 303,700 deaths in 2040, from 207,000 in 2022.

This rising incidence and mortality rates are expected to drive the demand for advanced therapeutics in the forecasted period.

The high cost of advanced therapies can hinder treatment rates and restrain market growth.

Several innovative therapies were approved by the regulatory bodies for use in ovarian cancer along with chemotherapy. These innovations include targeted therapies such as monoclonal antibodies, and enzyme poly (ADP-ribose) polymerase (PARP) inhibitors. These drugs are prescribed to reduce the recurrence and delay the progression of ovarian cancer. However, these drugs come at high prices and cause a high economic burden to the patient. This high cost may result to a decreased adoption rate among low and middle-income patient populations.

For instance, a study published in PLoS ONE journal in February 2024, stated that treatment of ovarian cancer patients with olaparib in Malaysia is expensive and may reflect an incremental cost of US$ 33,213. The life expectancy of patients treated with olaparib has increased by 3.05 years. This reflects an incremental cost-effectiveness ratio (ICER) of US$ 10,895 per life year gained.

Segment Analysis

The global ovarian cancer drugs market is segmented based on type, drug class, and region.

Drug Class:

Targeted therapy is dominating the ovarian cancer drugs market with the highest share in 2023

Targeted therapy drugs are approved for ovarian cancer as a maintenance therapy to improve the overall survival rate. These currently approved drugs include monoclonal antibodies such as bevacizumab, mirvetuximab soravtansine-gynx, and PARP inhibitors such as olaparib, niraparib, and rucaparib. The introduction of these into the market has revolutionized ovarian therapeutics. These drugs improved the survival rate, life expectancy, and quality of life, and reduced the recurrence rate.

At present PARP inhibitors have the major market share due to their high cost. These drugs are expensive and occupy a major share of the patient's out-of-pocket costs. Moreover, these drugs retain brand exclusivity and their manufacturers generate higher revenues. This is the major contributing factor for the dominance of targeted therapy in the ovarian cancer drugs market.

For instance, Zejula (niraparib) a PARP inhibitor dedicated for the treatment of advanced ovarian cancer, has reported sales of US$ 565 million in 2023. This single drug represents 15% of the 2023 ovarian cancer market share. Moreover, in 2024 a novel antibody-drug conjugate (Elahere) was launched in the U.S. and European market for the treatment of platinum-resistant ovarian cancer. The drug has reported sales of US$ 139 million in the first quarter of its launch.

There are several targeted therapies in the clinical pipeline which are anticipated to make market entry in the forecasted period. This will propel the targeted therapy market with the highest CAGR.

Geographical Analysis

North America is expected to hold a significant share of the ovarian cancer drugs market.

North America is expected to hold a significant market share due to the availability of advanced therapies. North America, being the leader in the healthcare industry, pharmaceutical companies heavily invest in developing novel therapies, and launch their product first in the region. Moreover, the demand from the patient population for these novel therapies is also higher. The patient population in the region gets first access to the medicine, and also manufacturers capture most of their revenue from the region.

For instance, in 2024, AbbVie first launched Elahere in the U.S. market and has already generated US$ 139 million in one quarter. This signifies the higher adoption rates of advanced therapies in the region.

Moreover, the rising incidence and mortality of ovarian cancer in the region is a significant contributing factor to the market growth in North America. As per the International Agency for Research on Cancer, the ovarian cancer incidence is projected to reach 30.4 thousand cases in 2040 from 24.5 thousand cases in 2022.

Competitive Landscape

The major global players in the ovarian cancer drugs market are AbbVie Inc., AstraZeneca., Merck & Co., Inc., GSK plc., pharmaand GmbH., Pfizer Inc., Amneal Pharmaceuticals LLC., Amgen, Inc., Sanofi, Teva Pharmaceuticals USA, Inc.

Key Developments

• In March 2024, The U.S. Food and Drug Administration approved ELAHERE (mirvetuximab soravtansine-gynx) and antibody-drug conjugate for the treatment of folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
• Following the U.S. FDA approval, ELAHERE received a European Commission nod for marketing authorization in November 2024, for the Treatment of platinum-resistant ovarian cancer. ELAHERE is developed by ImmunoGen, Inc., an AbbVie company.
• In July 2024, the U.S. FDA approved TEPYLUTE, a liquid form of thiotepa developed by SHORLA ONCOLOGY for the treatment of breast and ovarian cancer. This new formulation is designed to eliminate the complexities in the reconstitution of thiotepa and provide consistent dosing accuracy.
• On December 9, 2024, Merck & Co., Inc. announced results from the phase 3 KEYLYNK-001 trial that has evaluated KEYTRUDA (pembrolizumab) an immunotherapy drug combined with chemotherapy followed by maintenance therapy with LYNPARZA (Olaparib), with or without bevacizumab, as a first-line treatment for people with BRCA non-mutated advanced epithelial ovarian cancer. The therapy has met the primary end-point but has failed to meet the secondary end-points.

Emerging Players

The emerging players in the anti-amyloid monoclonal antibodies market include Corcept Therapeutics, Incorporated, SHORLA ONCOLOGY, DAIICHI SANKYO COMPANY, LIMITED., Zentalis Pharmaceuticals., Shenzhen Chipscreen Biosciences Co., Ltd., etc.

• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global ovarian cancer drugs market report would provide approximately 54 tables, 43 figures, and 184 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising incidence and mortality of ovarian cancer.
    • 4.1.1.2. Rising product development activities
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of advanced therapies
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Epithelial Ovarian Carcinomas*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Germ Cell Tumors
• 6.4. Stromal Cell Tumors
• 6.5. Borderline

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Chemotherapeutics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.2.1. Carboplatin
    • 7.2.2.2. Cisplatin
    • 7.2.2.3. Paclitaxel
    • 7.2.2.4. Docetaxel
    • 7.2.2.5. Others
• 7.3. Targeted Therapies
  • 7.3.1. Monoclonal Antibodies
  • 7.3.2. PARP Inhibitors
  • 7.3.3. Olaparib
  • 7.3.4. Niraparib
  • 7.3.5. Rucaparib
• 7.4. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.4.1. U.S.
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.4.1. Germany
    • 8.3.4.2. U.K.
    • 8.3.4.3. France
    • 8.3.4.4. Spain
    • 8.3.4.5. Italy
    • 8.3.4.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.4.1. Brazil
    • 8.4.4.2. Argentina
    • 8.4.4.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.4.1. China
    • 8.5.4.2. India
    • 8.5.4.3. Japan
    • 8.5.4.4. South Korea
    • 8.5.4.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. AbbVie Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. AstraZeneca.
• 10.3. Merck & Co., Inc.
• 10.4. GSK plc.
• 10.5. pharmaand GmbH.
• 10.6. Pfizer Inc.
• 10.7. Amneal Pharmaceuticals LLC.
• 10.8. Amgen, Inc.
• 10.9. Sanofi
• 10.10. Teva Pharmaceuticals USA, Inc.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us